Mereo BioPharma Group plc Holding(s) in Company (1608P)
05 Junho 2020 - 11:55AM
UK Regulatory
TIDMMPH
RNS Number : 1608P
Mereo BioPharma Group plc
05 June 2020
TR-1: S tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the Mereo BioPharma Group Plc
underlying issuer of existing shares
to which voting rights are attached
(ii) :
----------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify)(iii) :
----
3. Details of person subject to the notification obligation (iv)
Name OrbiMed Advisors LLC
City and country of registered office Delaware, USA
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v)
Name OrbiMed Private Investment VII, LP
OrbiMed Partners Master Fund Limited
OrbiMed Genesis Master Fund, LP
----------------------------------------------
City and country of registered office Delaware, USA
(if applicable) Bermuda
Cayman Islands
----------------------------------------------
5. Date on which the threshold was 3 June 2020
crossed or reached (vi) :
----------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 5 June 2020
----------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer (vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ ---------------------- --------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 9.39% 9.39% 213,652,487
------------------ ---------------------- --------------- --------------------
Position of
previous notification
(if
applicable)
------------------ ---------------------- --------------- --------------------
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares (ix)
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
--------------------------
Ordinary shares
GB00BZ4G2K23 20,061,437 9.39%
---------------------- -------------------------- ------------------------- ---------------------
SUBTOTAL 8. A 20,061,437 9.39%
-------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion Period rights that may rights
instrument (x) (xi) be acquired if
the instrument
is
exercised/converted.
----------- ------------------------------ -------------------------------- ---------------------
SUBTOTAL 8. B 1
------------------------------ -------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date (x) Conversion cash voting rights rights
instrument Period (xi) settlement
(xii)
---------------- -------------------- -------------------- --------------------
SUBTOTAL 8.B.2
-------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer (xiii)
Full chain of controlled undertakings through which the voting rights x
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (xiv) (please add additional
rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
---------------------- --------------------- ------------------------
OrbiMed Private
Investments VII,
LP 5.01%
---------------------- --------------------- ------------------------
OrbiMed Partners
Master Fund Limited 3.13%
---------------------- --------------------- ------------------------
OrbiMed Genesis
Master Fund, LP 1.25%
---------------------- --------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
-----------------------------------------------
The number and % of voting rights
held
-----------------------------------------------
The date until which the voting rights
will be held
-----------------------------------------------
11. Additional information (xvi)
10,699,433 ordinary shares are held of record by OrbiMed Private Investments
VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general
partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors") is
the managing member of GP VII. By virtue of such relationships, GP VII
and OrbiMed Advisors may be deemed to have voting power and investment
power over the securities held by OPI VII and as a result, may be deemed
to have an interest in such securities.
6,687,146 ordinary shares are held of record by OrbiMed Partners Master
Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the
investment advisor of OPM. OrbiMed Capital is a relying advisor of OrbiMed
Advisors.
2,674,858 ordinary shares are held of record by OrbiMed Genesis Master
Fund, LP ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general
partner of Genesis. OrbiMed Advisors is the managing member of Genesis
GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors
may be deemed to have voting power and investment power over the securities
held by Genesis and as a result, may be deemed to have an interest in
such securities.
OrbiMed Advisors and OrbiMed Capital exercises voting and investment
power through a management committee comprised of Carl L. Gordon, Sven
H. Borho, and Jonathan T. Silverstein.
Place of completion New York, NY USA
Date of completion 5 June 2020
-----------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLFAMITMTAMBJM
(END) Dow Jones Newswires
June 05, 2020 10:55 ET (14:55 GMT)
Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
